The specialized contract manufacturing sector for lentiviral vectors has grown into a substantial economic force within the broader biopharmaceutical industry. Its expansion is a direct consequence of the overwhelming clinical success and commercial potential demonstrated by gene and cell therapies worldwide. These complex therapeutic modalities rely entirely on the consistent, high-quality...